L’Oréal Groupe acquires majority stake in Medik8

In a major development, L’Oréal Groupe announced the signing of an agreement to acquire a majority stake in the British skin care brand Medik8. 

Terms of the transaction include Inflexion, a European mid-market private equity firm, remaining as its minority shareholder. In addition, the founder will continue to serve on the board alongside the current management committee. 

“We are delighted to welcome Medik8 to the L’Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,” explained Cyril Chapuy, president of L’Oréal Luxe. “We share a strong belief in Medik8's global potential and are excited to embark on this journey together, to build a powerful and impactful brand presence worldwide.” 

[Related: Huda Kattan reclaims full ownership of Huda Beauty]

Founded by Elliot Isaacs, Medik8 is best known for its Crystal Retinal serum and trademarked CSA Philosophy: Vitamin C and Sunscreen by Day, Vitamin A by night. 

“This is an exciting day for Medik8,” said Simon Coble, CEO of Medik8. “I am delighted to be joining forces with a company which shares our vision for the brand’s future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8’s journey, as we work together to bring our innovative products to a wider audience.”

L’Oréal will start consolidating Medik8 sales from the date of the closing of the transaction. As part of the agreement, L’Oréal has also secured rights to buyout in full the minority shareholders.

The transaction is expected to be completed in the next few months after regulatory approvals and other customary conditions.